Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study
- PMID: 36836211
- PMCID: PMC9967664
- DOI: 10.3390/jcm12041676
Predictive Role of hsCRP in Recurrent Stroke Differed According to Severity of Cerebrovascular Disease: Analysis from a Prospective Cohort Study
Abstract
Elevated levels of high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of recurrent stroke. However, it is still unknown whether the predictive value of hsCRP differed according to the severity of cerebrovascular disease. We used the cohort of the prospective multicenter cohort study of the Third China National Stroke Registry (CNSR-III), in which 10,765 consecutive patients with acute ischemic stroke or transient ischemic attack (TIA) had hsCRP levels measured. Patients were classified into minor stroke, or TIA, and non-minor stroke. The primary outcome was a new stroke within 1 year. Cox proportional hazards models were used to assess the association of hsCRP and its outcome. Elevated levels of hsCRP were associated with an increased risk of recurrent stroke in minor stroke or TIA patients, irrespective of using a National Institutes of Health Stroke Scale (NIHSS) score of ≤3 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.48; 95% CI, 1.12-1.97; p = 0.007) or ≤5 (the highest quartile vs. the lowest quartile: adjusted hazard ratio, 1.45; 95% CI, 1.15-1.84; p = 0.002) to define minor stroke. Such association was more apparent in the large-artery atherosclerosis subtype. However, for the patients with non-minor stroke, the association of hsCRP with recurrent stroke disappeared.
Keywords: biomarkers; inflammation; prognosis; stroke; transient ischemic attack.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Association Between High-Sensitivity C-Reactive Protein and Prognosis in Different Periods After Ischemic Stroke or Transient Ischemic Attack.J Am Heart Assoc. 2022 Jul 5;11(13):e025464. doi: 10.1161/JAHA.122.025464. Epub 2022 Jun 29. J Am Heart Assoc. 2022. PMID: 35766270 Free PMC article.
-
Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study.J Neuroinflammation. 2022 Jun 6;19(1):131. doi: 10.1186/s12974-022-02467-1. J Neuroinflammation. 2022. PMID: 35761288 Free PMC article.
-
High-Sensitivity C-reactive Protein and Intracranial Arterial Stenosis Predicted Recurrent Stroke and Dependence or Death in Minor Stroke or Transient Ischemic Attack.J Atheroscler Thromb. 2024 Mar 1;31(3):249-258. doi: 10.5551/jat.64229. Epub 2023 Sep 12. J Atheroscler Thromb. 2024. PMID: 37704441 Free PMC article.
-
Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients.Stroke. 2021 Aug;52(9):2827-2836. doi: 10.1161/STROKEAHA.120.033152. Epub 2021 Jul 20. Stroke. 2021. PMID: 34281380
-
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.Stroke. 2016 Aug;47(8):2025-30. doi: 10.1161/STROKEAHA.116.012901. Epub 2016 Jun 21. Stroke. 2016. PMID: 27328699
Cited by
-
Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-controlled Trial.Rev Recent Clin Trials. 2025;20(1):59-67. doi: 10.2174/0115748871325292240904060109. Rev Recent Clin Trials. 2025. PMID: 39301899 Clinical Trial.
-
Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.BMJ. 2024 Jun 26;385:e079061. doi: 10.1136/bmj-2023-079061. BMJ. 2024. PMID: 38925803 Free PMC article. Clinical Trial.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials